ALK and non-small cell lung carcinoma: Anaplastic lymphoma kinase (ALK)-targeted therapies, such as crizotinib, ceritinib, brigatinib, loratinib, and alectinib, are well-established FDA-approved treatment options in ALK-translocated non-small cell lung cancer (NSCLC).